Figure 1.
Menin inhibition demonstrates antileukemia activities and prolongs mouse survival, which is further enhanced by Bcl-2 inhibition in an NPM1c/FLT3-ITD/TKD PDX model. (A) The mouse model and experimental scheme. Percentage of huCD45+ cells in peripheral blood at 2 weeks (B) and at 4 weeks (C) and at the end of the treatment in BM (D) and spleen (E), as determined by flow cytometry. (F) Spleen weight and size at the end of the treatment. (G) Survival curve. Mouse survival was estimated using the Kaplan-Meier method, and survival data were analyzed using the log-rank test. Differences between groups were determined using the Student t test. Values of P ≤.05 were considered statistically significant. D, day; PB, peripheral blood; PK, pharmacokinetics; SNDX, SNDX-50469; VEN, venetoclax.

Menin inhibition demonstrates antileukemia activities and prolongs mouse survival, which is further enhanced by Bcl-2 inhibition in an NPM1c/FLT3-ITD/TKD PDX model. (A) The mouse model and experimental scheme. Percentage of huCD45+ cells in peripheral blood at 2 weeks (B) and at 4 weeks (C) and at the end of the treatment in BM (D) and spleen (E), as determined by flow cytometry. (F) Spleen weight and size at the end of the treatment. (G) Survival curve. Mouse survival was estimated using the Kaplan-Meier method, and survival data were analyzed using the log-rank test. Differences between groups were determined using the Student t test. Values of P ≤.05 were considered statistically significant. D, day; PB, peripheral blood; PK, pharmacokinetics; SNDX, SNDX-50469; VEN, venetoclax.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal